ALK and non-small cell lung carcinoma: In this case as seen in NSCLC the superiority of alectinib compared to an earlier generation ALK inhibitor, such as crizotinib, the authors wanted to avoid potential resistance that can occur with crizotinib, but that alectinib can overcome as well as the lower rates of toxicity.